Abstract
Studies of longitudinal trends of depressive symptoms in young people could provide insight into aetiologic mechanism, heterogeneity and origin of common cardiometabolic comorbidities for depression. Depression is associated with immunological and metabolic alterations, but immunometabolic characteristics of developmental trajectories of depressive symptoms remain unclear. Using depressive symptoms scores measured on 10 occasions between ages 10 and 25 years in the Avon Longitudinal Study of Parents and Children (n=7302), we identified four distinct trajectories: low-stable (70% of the sample), adolescent-limited (13%), adulthood-onset (10%) and adolescent-persistent (7%). We examined associations of these trajectories with: i) anthropometric, cardiometabolic and psychiatric phenotypes using multivariable regression (n=1709-3410); ii) 67 blood immunological proteins and 57 metabolomic features using empirical Bayes moderated linear models (n=2059 and n=2240 respectively); and iii) 28 blood cell counts and biochemical measures using multivariable regression (n=2256). Relative to the low-stable group, risk of depression and anxiety in adulthood was higher for all other groups, especially in the adolescent-persistent (ORdepression=22.80, 95% CI 15.25-34.37; ORGAD=19.32, 95% CI 12.86-29.22) and adulthood-onset (ORdepression=7.68, 95% CI 5.31-11.17; ORGAD=5.39, 95% CI 3.65-7.94) groups. The three depression-related trajectories vary in their immunometabolic profile, with evidence of little or no alterations in the adolescent-limited group. The adulthood-onset group shows widespread classical immunometabolic changes (e.g., increased immune cell counts and insulin resistance), while the adolescent-persistent group is characterised by higher BMI both in childhood and adulthood with few other immunometabolic changes. These findings point to distinct mechanisms and intervention opportunities for adverse cardiometabolic profile in different groups of young people with depression.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by the Tackling Multimorbidity at Scale Strategic Priorities Fund programme (MR/W014416/1) delivered by the UK Medical Research Council (MRC) and the UK National Institute for Health Research (NIHR) in partnership with the UK Economic and Social Research Council and in collaboration with the UK Engineering and Physical Sciences Research Council. RSMT, DS and MLW are supported by this grant. ASFK is supported by a Wellcome Early Career Award (227063/Z/23/Z). NAD was supported by an NIHR Clinical Lectureship in General Adult Psychiatry. MBMvdB acknowledges additional funding support from the MRC (MR/W028395/1, MR/W020297/1, MR/T033045/1 and MR/S037667/1), NIMH (U01MH119758), the Wellcome Trust (226709/Z/22/Z) and Welsh Government (HS 22 04). NJT is a director of the MRC/ESRC/UKRI supported Population Research UK Coordination Hub (ES/Y008340/1), supported by a Wellcome Trust Investigator award (202802/Z/16/Z), is the PI of the Avon Longitudinal Study of Parents and Children (MRC & WT 217065/Z/19/Z), is supported by the University of Bristol NIHR Biomedical Research Centre (BRC-1215-2001), the MRC Integrative Epidemiology Unit (MC_UU_00011/1), CRUK and works within the CRUK Integrative Cancer Epidemiology Programme (C18281/A29019) and with support from CRUK (PRCPJT-May22\100028). GMK acknowledges funding support from the MRC (MC_UU_00032/06), which forms part of the MRC Integrative Epidemiology Unit at the University of Bristol. This grant also supports HF. GMK acknowledges additional funding from the Wellcome Trust (201486/Z/16/Z and 201486/B/16/Z), the MRC (MR/W014416/1; MR/S037675/1; and MR/Z50354X/1), and the NIHR Bristol Biomedical Research Centre (NIHR 203315). The views expressed are those of the authors and not necessarily those of the UK NIHR or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the study was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees. Consent for biological samples has been collected in accordance with the Human Tissue Act (2004). Informed consent for the use of data collected via questionnaires and clinics was obtained from participants following the recommendations of the ALSPAC Ethics and Law Committee at the time.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* A list of members and their affiliations appear at the end of the paper.
ruby.tsang{at}bristol.ac.uk, d.stow{at}qmul.ac.uk, akwong{at}ed.ac.uk, nick.donnelly{at}bristol.ac.uk, holly.fraser{at}bristol.ac.uk, ines.barroso{at}exeter.ac.uk, holmanspa{at}cardiff.ac.uk, owenmj{at}cardiff.ac.uk, m.l.wood{at}leeds.ac.uk, vandenbreemb{at}cardiff.ac.uk, n.j.timpson{at}bristol.ac.uk, golam.khandaker{at}bristol.ac.uk
Data Availability
ALSPAC data access is through a system of managed open access. Information on how to request access to ALSPAC data can be found on the ALSPAC website (http://www.bristol.ac.uk/alspac/researchers/access/).
